CSL Bioplasma includes our contract fractionation operations in Melbourne, the commercial operations of CSL Behring Asia (excluding Japan) and our Immunohaematology Group.

Several industry policy changes have contributed to an 8% reduction in sales revenue to $191 million this year. Sales of our plasma-derived therapeutics were affected by the first full year of Australian Government funding for imported recombinant coagulation factors. This was also the first full year of the Plasma Products Agreement (PPA) with the Australian National Blood Authority (NBA) under a new pricing policy for fractionation services. The new Australian procurement arrangements introduced by the NBA for the diagnostics sector also had an impact on our market share for immunohaematology products.

Under the PPA, CSL Bioplasma has fractionated approximately 300 tonnes of Australian plasma this year producing sufficient life-saving, plasma-derived therapeutics to treat approximately 200,000 Australians.

We are achieving higher yields of intravenous immunoglobulin as a result of innovative improvements to the fractionation process used for Intragam® P. Our industry-leading intravenous immunoglobulin yield allows us to optimise the extraction of IVIg from the voluntary blood donations collected in Australia, and therefore provide greater quantities of this life-saving product to our health care professionals.

During the year, we launched the Mix2Vial, an improved reconstitution device designed to enhance ease of use and patient safety when reconstituting our lyophilised coagulation factors including Biostate® (Factor VIII), MonoFix® (Factor IX), and Prothrombinex™ - HT (Factors II, IX and X concentrate).

Significant sales revenues continue to be generated through the customised contract fractionation operations we provide to the blood services of New Zealand, Malaysia, Hong Kong and Singapore. This year, we extended our contract fractionation agreement with Hong Kong, and renegotiated our manufacturing agreement with the New Zealand Blood Service. Renewing these agreements reinforces the position of CSL Bioplasma as the plasma fractionator of choice in the Asia Pacific.

Strong demand for albumin in Asia, particularly China, underpinned CSL Behring Asia’s 20% growth in sales revenue. We continue to build our infrastructure in China and now have offices in Beijing, Shanghai, Guangzhou and Chengdu.

Back | Next